WordNet

PrepTutorEJDIC

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

Schmid H1, Lederer SR2.
Expert opinion on pharmacotherapy.Expert Opin Pharmacother.2015 Oct;16(14):2179-91. doi: 10.1517/14656566.2015.1079622. Epub 2015 Aug 18.
INTRODUCTION: Hyperphosphatemia is a frequent complication of chronic kidney disease and is associated with increased mortality. Despite side effects, risk of accumulation and high costs, phosphate binders (PBs) have become the crucial cornerstone of therapy. The iron-containing PB sucroferric oxyhy
PMID 26293683

Ferric Citrate Reduces Intravenous Iron and Erythropoiesis-Stimulating Agent Use in ESRD.

Umanath K1, Jalal DI2, Greco BA3, Umeukeje EM4, Reisin E5, Manley J6, Zeig S7, Negoi DG8, Hiremath AN9, Blumenthal SS10, Sika M4, Niecestro R11, Koury MJ12, Ma KN13, Greene T13, Lewis JB4, Dwyer JP4; Collaborative Study Group.
Journal of the American Society of Nephrology : JASN.J Am Soc Nephrol.2015 Oct;26(10):2578-87. doi: 10.1681/ASN.2014080842. Epub 2015 Mar 3.
Ferric citrate (FC) is a phosphate binder with shown efficacy and additional effects on iron stores and use of intravenous (iv) iron and erythropoiesis-stimulating agents (ESAs). We provide detailed analyses of changes in iron/hematologic parameters and iv iron/ESA use at time points throughout the
PMID 25736045

Characterizing and optimizing magnetosome production of Magnetospirillum sp. XM-1 isolated from Xi'an City Moat, China.

Wang Y1, Lin W1, Li J1, Zhang T1, Li Y2, Tian J2, Gu L3, Heyden YV4, Pan Y5.
FEMS microbiology letters.FEMS Microbiol Lett.2015 Sep 15. pii: fnv167. [Epub ahead of print]
Pure culture of magnetotactic bacteria (MTB) is desirable to understand their physiology, evolution and biomineralization. Here, we report a new strain Magnetospirillum sp. XM-1 that was recently isolated and cultivated from the eutrophic city moat of Xi'an, China. Magnetosome biomineralization, cry
PMID 26376913

Effect of a Ferric Citrate Formulation, a Phosphate Binder, on Oxidative Stress in Chronic Kidney Diseases-Mineral and Bone Disorder Patients Receiving Hemodialysis: A Pilot Study